{"id":"pla-mtx-switched-to-aba-mtx-db","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Infection (upper respiratory, urinary tract)"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Dizziness"},{"rate":"5-10","effect":"Hypertension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Abatacept selectively modulates T-cell activation by binding to CD80 and CD86 on antigen-presenting cells, preventing engagement with CD28 on T cells. This blocks the second signal required for full T-cell activation and proliferation. When combined with methotrexate, a disease-modifying antirheumatic drug (DMARD), the dual mechanism provides enhanced suppression of inflammatory pathways in autoimmune conditions.","oneSentence":"Abatacept (ABA) is a T-cell costimulation inhibitor that blocks the interaction between antigen-presenting cells and T cells, reducing inflammatory immune responses when combined with methotrexate (MTX).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:26:22.852Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis (as part of combination therapy with MTX)"},{"name":"Polyarticular juvenile idiopathic arthritis"}]},"trialDetails":[{"nctId":"NCT00095147","phase":"PHASE3","title":"Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2005-02","conditions":"Rheumatoid Arthritis","enrollment":431}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Orencia"],"phase":"phase_3","status":"active","brandName":"PLA + MTX switched to ABA+ MTX, DB","genericName":"PLA + MTX switched to ABA+ MTX, DB","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Abatacept (ABA) is a T-cell costimulation inhibitor that blocks the interaction between antigen-presenting cells and T cells, reducing inflammatory immune responses when combined with methotrexate (MTX). Used for Rheumatoid arthritis (as part of combination therapy with MTX), Polyarticular juvenile idiopathic arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}